References
Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies-A report from the Children’s Cancer Group Study. Med Pediatr Oncol. 2001;36:612–22.
Matthay KK, Blaes F, Hero B, Plantaz D, De Alarcon P, Mitchell WG, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005;228:275–82.
Mitchell WG, Davalos-Gonzalez Y, Brumm VL, Aller SK, Burger E, Turkel SB, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: Developmental and neurologic sequelae. Pediatrics. 2002;109:86–98. Erratum in: Pediatrics 2002;110:853–4.
Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics. 2005;115:e115–9.
Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26:66–73.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sinha, S., Sarin, Y.K. Rituximab for Opsoclonus Myoclonus Ataxia Syndrome Associated with Neuroblastoma. Indian J Pediatr 81, 218–219 (2014). https://doi.org/10.1007/s12098-013-1042-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-013-1042-7